P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 2, 2005, Pages 110-116

  Kamath, Amrita V ^a   Chong, Saeho ^a   Chang, Ming ^a   Marathe, Punit H ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Absorption; Bioavailability; CDK 2 inhibitor; Metabolism; P glycoprotein; Rat pharmacokinetics

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; GLYCOPROTEIN P; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BILE DUCT; BINDING ASSAY; BRAIN; CANCER CHEMOTHERAPY; CANNULATION; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG PENETRATION; DRUG SCREENING; DRUG UPTAKE; FIRST PASS EFFECT; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM; KNOCKOUT MOUSE; LIVER METABOLISM; LIVER MICROSOME; MALE; MODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; WILD TYPE;

ABSORPTION; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CACO-2 CELLS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOGS; HUMANS; MALE; MICE; MICROSOMES, LIVER; OXAZOLES; P-GLYCOPROTEIN; PHOTOAFFINITY LABELS; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLES;

EID: 12144251786     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0873-3     Document Type: Article

References (22)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398
2. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095
3. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV (1998) Photoaffinity labeling of human P-glycoprotein: effect of modulator interaction and ATP hydrolysis on substrate binding. Methods Enzymol 292:318-328
4. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker, New York
5. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427
6. Hidalgo IJ, Raub TJ, Borchardt RT (1989) Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749
7. Hunter T, Pines J (1994) Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 79:573-582
8. Kim KS, Kimball SD, Misra RN, Rawlins DB, Hunt JT, Xiao HY, Lu S, Qian L, Han WC, Shan W, Mitt T, Cai ZW, Poss MA, Zhu H, Sack JS, Tokarski JS, Chang CY, Pavletich N, Kamath A, Humphreys WG, Marathe P, Bursuker I, Kellar KA, Roongta U, Batorsky R, Mulheron JG, Bol D, Fairchild CR, Lee FY, Webster KR (2002) Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem 45:3905-3927
9. Mandagere AK, Thompson TN, Hwang KK (2002) Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 45:304-311
10. Meunier V, Bourrie M, Berger Y, Fabre G (1995) The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol Toxicol 11:187-194
11. Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA, Hunt JT, Rawlins DB, Shan W, Ahmed SZ, Qian L, Chen BC, Zhao R, Bednarz MS, Kellar KA, Mulheron JG, Batorsky R, Roongta U, Kamath A, Marathe P, Ranadive SA, Sack JS, Tokarski JS, Pavletich NP, Lee FY, Webster KR, Kimball SD (2004) N-(cycloalkylamino)acyl-2- aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1- dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 47:1719-1728
12. Pines J (1994) The cell cycle kinases. Semin Cancer Biol 5:305-313
13. Pines J (1995) Cyclins, CDKs and cancer. Semin Cancer Biol 6:63-72
14. Raucy JL, Lasker JM (1991) Isolation of P450 enzymes from human liver. Methods Enzymol 206:577-587
15. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502
16. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524
17. Senderowicz AM (2003) Small-molecule cyclin-dependent kinase modulators. Oncogene 22:6609-6620
18. Silverman JA (1999) Multidrug-resistance transporters. Pharm Biotechnol 12:353-386
19. Tanigawara Y (2000) Role of P-glycoprotein in drug disposition. Ther Drug Monit 22:137-140
20. van Asperen J, Mayer U, van Tellingen O, Beijnen JH (1997) The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 86:881-884
21. Wacher VJ, Salphati L, Benet LZ (2001) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 46:89-102
22. Webster KR (2000) Therapeutic potential of targeting the cell cycle. Chem Res Toxicol 13:940-943